Cargando…

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

Over three decades have passed since the first report on the expression of CA125 by ovarian tumors. Since that time our understanding of ovarian cancer biology has changed significantly to the point that these tumors are now classified based on molecular phenotype and not purely on histological attr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Felder, Mildred, Kapur, Arvinder, Gonzalez-Bosquet, Jesus, Horibata, Sachi, Heintz, Joseph, Albrecht, Ralph, Fass, Lucas, Kaur, Justanjyot, Hu, Kevin, Shojaei, Hadi, Whelan, Rebecca J, Patankar, Manish S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046138/ https://www.ncbi.nlm.nih.gov/pubmed/24886523 http://dx.doi.org/10.1186/1476-4598-13-129

Ejemplares similares

MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
por: Gubbels, Jennifer AA, et al.
Publicado: (2010)

HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy
por: Xiang, Xinran, et al.
Publicado: (2011)

Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes
por: Belisle, Jennifer A, et al.
Publicado: (2010)

Modulation of oxidative stress and subsequent induction of apoptosis and endoplasmic reticulum stress allows citral to decrease cancer cell proliferation
por: Kapur, Arvinder, et al.
Publicado: (2016)

M2 macrophages induce ovarian cancer cell proliferation via a heparin binding epidermal growth factor/matrix metalloproteinase 9 intercellular feedback loop
por: Carroll, Molly J., et al.
Publicado: (2016)

Oxidative stress induced by the anti-cancer agents, plumbagin, and atovaquone, inhibits ion transport through Na(+)/K(+)-ATPase
por: Alharbi, Yousef, et al.
Publicado: (2020)

Plumbagin-induced oxidative stress leads to inhibition of Na(+)/K(+)-ATPase (NKA) in canine cancer cells
por: Alharbi, Yousef, et al.
Publicado: (2019)

Individual recombinant repeats of MUC16 display variable binding to CA125 antibodies
por: Wang, Chien-Wei, et al.
Publicado: (2023)

CA125/MUC16 Is Dispensable for Mouse Development and Reproduction
por: Cheon, Dong-Joo, et al.
Publicado: (2009)

Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in Relation to Ovarian Cancer Risk and Survival
por: Williams, Kristina A., et al.
Publicado: (2014)

Conflicting Views on the Molecular Structure of the Cancer Antigen CA125/MUC16
por: Bouanene, Houda, et al.
Publicado: (2010)

Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies
por: Goodell, Cara AR, et al.
Publicado: (2009)

Terpenoids from Zingiber officinale (Ginger) Induce Apoptosis in Endometrial Cancer Cells through the Activation of p53
por: Liu, Yang, et al.
Publicado: (2012)

Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells
por: Huang, Yao, et al.
Publicado: (2021)

DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1
por: Connor, Joseph P, et al.
Publicado: (2012)

Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion
por: Rao, Thapi D., et al.
Publicado: (2015)

Expression of MUC16/CA125 Is Associated with Impaired Survival in Patients with Surgically Resected Cholangiocarcinoma
por: Kinzler, Maximilian N., et al.
Publicado: (2022)

Trans10,cis12 conjugated linoleic acid inhibits proliferation and migration of ovarian cancer cells by inducing ER stress, autophagy, and modulation of Src
por: Shahzad, Mian M. K., et al.
Publicado: (2018)

Oxidative stress via inhibition of the mitochondrial electron transport and Nrf-2-mediated anti-oxidative response regulate the cytotoxic activity of plumbagin
por: Kapur, Arvinder, et al.
Publicado: (2018)

The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity
por: Saad, Hebatallah M., et al.
Publicado: (2022)

Oxidative Phosphorylation: A Target for Novel Therapeutic Strategies Against Ovarian Cancer
por: Nayak, Amruta P., et al.
Publicado: (2018)

MUC16/CA125 in the Context of Modular Proteins with an Annotated Role in Adhesion-Related Processes: In Silico Analysis
por: Jankovic, Miroslava, et al.
Publicado: (2012)

Atovaquone: An Inhibitor of Oxidative Phosphorylation as Studied in Gynecologic Cancers
por: Kapur, Arvinder, et al.
Publicado: (2022)

Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation
por: Chen, Shih-Hsun, et al.
Publicado: (2013)

The detection, treatment, and biology of epithelial ovarian cancer
por: Gubbels, Jennifer AA, et al.
Publicado: (2010)

Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
por: Einama, Takahiro, et al.
Publicado: (2021)

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression
por: Matte, Isabelle, et al.
Publicado: (2014)

High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations
por: Wang, Qinghua, et al.
Publicado: (2020)

Transcriptomic profile of intrinsically chemoresistant acute myeloid leukemia patients
por: Horibata, Sachi
Publicado: (2019)

Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells
por: Comamala, M, et al.
Publicado: (2011)

Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB
por: Morgado, Micaela, et al.
Publicado: (2016)

Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies
por: Stasenko, Marina, et al.
Publicado: (2021)

NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects
por: Nicolaides, Nicholas C., et al.
Publicado: (2023)

ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells
por: lei, Yuanyuan, et al.
Publicado: (2020)

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
por: Gubbels, Jennifer AA, et al.
Publicado: (2006)

Characterization of Cell-Bound CA125 on Immune Cell Subtypes of Ovarian Cancer Patients Using a Novel Imaging Platform
por: González, Germán, et al.
Publicado: (2021)

Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis
por: Yamamoto-Furusho, Jesús K., et al.
Publicado: (2015)

Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling)
por: Hanson, Ryan L., et al.
Publicado: (2016)

Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer
por: Lakatos, Kornél, et al.
Publicado: (2022)

Peritoneal trauma releases CA125?
por: Redman, C. W., et al.
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_gk90n228h1kuvubg1taogu4mve